

ACTIVITY DISCLOSURE STATEMENT Advances in Cytology and Small Biopsies 732036-2502 June 9-11, 2025

Accreditation

In support of improving patient care, Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Accreditation

NAME

The Harvard Medical School designates this live activity for a maximum of 25.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All individuals in a position to control the content of this activity have been asked to disclose any relationship they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The following planners, speakers, and content reviewers have reported relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated:

COMPANY

RELATIONSHIP

COMPANY	RELATIONSHIP
Boston Scientific	Consultant
PathAI	Consultant
Ultivue, Inc.	Consultant
Genetch Lilly AstraZeneca Bristol Myers Squibb Lilly	Research Support, Consultant Consultant Advisory Board/Committee Research Support Advisory Board/Committee
AIxMed	Advisory Board/Committee
Gala Therapeutics Galvanize Therapeutics Intuitive Surgical Ruby Robotics Veracyte Agilent Technologies	Consultant Consultant Consultant Consultant Consultant Consultant
	Boston Scientific PathAI Ultivue, Inc. Genetch Lilly AstraZeneca Bristol Myers Squibb Lilly AIxMed Gala Therapeutics Galvanize Therapeutics Intuitive Surgical Ruby Robotics Veracyte

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.